Abstract 289O
Background
Parathyroid neoplasms are characterized with hypersecretion of parathyroid hormone and potentially exhibit disruption of metabolic pathways. Mitochondria are essential for energy homeostasis and mitochondrial DNA (mtDNA) abnormalities are related to multiple types of malignancies. However, the status of mtDNA mutation and copy number variations in parathyroid carcinoma (PC) is not well known.
Methods
Ultra-deep targeted sequencing of mitochondrial genome was performed using tissues of 12 PCs and 12 parathyroid adenomas (PAs). Germline variants and somatic mutations in the mitochondrial genome were scanned and analysed in comparison with clinical features. The relative copy number of mtDNA in PCs and PAs was determined via quantitative real-time polymerase chain reaction.
Results
A total of 528 germline variants and 16 somatic mutations were identified in 24 samples of parathyroid neoplasms. All 62 non-synonymous germline variants in coding sequence (CDS) were predicted to be of low pathogenicity in PA and PC samples. Five somatic mutations with high pathogenicity in CDSs were identified in 4 (33.3%, 4/12) PC samples and 1 PA sample (8.3%, 1/12). A somatic mutation in a CDS was correlated with high mtDNA copy number in parathyroid neoplasm (p = 0.004), CDC73 gene mutation (p = 0.017) and PC recurrence (p = 0.024). More C-19 genotypes in the D310 region were found in PA than in the PC samples (3.5% vs 1.9%, p = 0.045).
Conclusions
More somatic CDS mutations with high pathogenicity were identified in PC than in PA. A high mtDNA copy number was found in parathyroid neoplasms with somatic CDS mutations and in PCs with CDC73 mutations and recurrence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS-I2M) (2017-I2M-1-001), Peking Union Medical College Innovative Team Development Program, the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32014) and the 2016 Peking Union Medical College Hospital Science Foundation for Junior Faculty (pumch-2016.2.7).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Molecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region
Presenter: Vikas Talreja
Session: Mini Oral session - Head and neck cancer
Resources:
Slides
Webcast
Long-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy
Presenter: Jingjing Miao
Session: Mini Oral session - Head and neck cancer
Resources:
Slides
Webcast
Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta Indonesia
Presenter: Susanna Hutajulu
Session: Mini Oral session - Head and neck cancer
Resources:
Slides
Webcast
292O - 90-day mortality in head and neck cancer after concurrent chemoradiotherapy
Presenter: Szu-Yuan Wu
Session: Mini Oral session - Head and neck cancer
Resources:
Abstract
Survival outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting
Presenter: Filipa Pontes
Session: Mini Oral session - Head and neck cancer
Resources:
Slides
Webcast